Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study
Double-Blind, Placebo-Controlled, Pilot Study, In Medical Patients With Prophylaxis Of Venous Thromboembolism in Primary Care
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Leon, Spain, 24005
- Pfizer Investigational Site
-
Madrid, Spain
- Pfizer Investigational Site
-
Madrid, Spain, 28001
- Pfizer Investigational Site
-
Parla, Spain
- Pfizer Investigational Site
-
Torremolinos, Spain, 29620
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 65 years
- Confinement to bed for more than 3 days, due to:
- Heart failure
- Exacerbated chronic obstructive pulmonary disease
- Acute rheumatic involvement
- Written informed consent
Exclusion Criteria:
- Cancer
- Anticoagulant treatment in the previous 3 months
- Stroke or major surgery in the previous 3 months
- Systolic pressure >200 mmHg or diastolic pressure >120 mmHg
- Known chronic hepatopathy
- Active hemorrhage in any site in the previous 3 months
- Active peptic ulcer
- Bacterial endocarditis
- Conditions that can increase the risk of hemorrhage
- Known coagulation disorders
- Hypersensitivity to heparin or HIT
- Life expectancy of less than 3 months
- Previous confinement to bed during more than 3 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo was administered with a daily injection of 0.2 mL by subcutaneous route.
The treatment duration was 7 days in a single daily injection throughout the bedridden period.
|
|
Active Comparator: Dalteparin sodium
|
Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route.
The treatment duration was 7 days in a single daily injection throughout the bedridden period.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of the endpoint made up of objectively demonstrated deep vein thrombosis (DVT), pulmonary embolism (PE) diagnosed by objective tests or death at the end of the follow-up period, 1 month after the end of the bedridden period.
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of symptomatic deep vein thrombosis (DVT), symptomatic pulmonary embolism (PE) and tolerability at the end of the follow-up period.
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FGMAEI-0042-046
- A6301036
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.